Dermatologic treatment during pregnancy: how to weigh the risk:benefit ratio for mother and fetus

References

• Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet356, 1735–1736 (2000).
   PubMed Web of Science ®Google Scholar
• Schirm E, Meijer WM, Tobi H, de Jong-van den Berg LT. Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system. Eur. J. Obstet. Gynecol. Reprod. Biol.114, 182–188 (2004).
   PubMed Web of Science ®Google Scholar
• Andrade SE, Gurwitz JH, Davis RL et al. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol.191, 398–407 (2004).
   PubMed Web of Science ®Google Scholar
• Guenther L. Skin drugs in pregnancy – which ones to use. Dermatol. Nurs.9, 233–236 (1997).
   PubMedGoogle Scholar
• Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int. J. Dermatol.41, 197–203 (2002).
   PubMed Web of Science ®Google Scholar
• Reed BR. Dermatologic drugs pregnancy and lactation. A conservative guide. Arch. Dermatol.133, 894–898 (1997).
   PubMedGoogle Scholar
• Briggs GG, Freeman RK, Yaffe J. Drugs in pregnancy and lactation. A Reference Guide to Fetal and Neonatal Risk (7th Edition). Lippincott, Williams and Wilkins, PA, USA 1858 (2005).
   Google Scholar
• Machet L, Vaillant L, Lorette G. Les risques des traitements topiques au cours de la grossesse. Ann. Dermatol. Venereol.119, 503–508 (1992).
   PubMed Web of Science ®Google Scholar
• Zesch A. Lokaltherapie in der Schwangerschaft. Hautarzt41, 365–368 (1990).
   PubMed Web of Science ®Google Scholar
• Sannerstedt R, Lundborg P, Danielsson BR et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf.14, 69–77 (1996).
   PubMed Web of Science ®Google Scholar
• Anonymous. Dictionnaire Vidal®. OVP, editions du Vidal®. Paris, France (2005).
   Google Scholar
• Goldsmith LA, Bolognia JL, Callen JP et al. American Academy of Dermatology. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J. Am. Acad. Dermatol.50, 900–906 (2004).
   PubMed Web of Science ®Google Scholar
• van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J. Eur. Acad. Dermatol. Venereol.11(Suppl. 1), S13–S19 (1998).
   PubMed Web of Science ®Google Scholar
• Seegmiller RE, Ford WX, Carter MW, Mitala JJ, Powers JJ. A developmental toxicity study of tretinoin administered topically and orally to pregnant Wistar rats. J. Am. Acad. Dermatol.36, S60–S66 (1997).
   Google Scholar
• Johnson EM. A risk assessment of topical tretinoin as a potential human developmental toxin based on animal and comparative human data. J. Am. Acad. Dermatol.36, S86–S90 (1997).
   Google Scholar
• Shapiro L, Pastuszak A, Curto G, Koren G. Is topical tretinoin safe during the first trimester? Can. Fam. Physician44, 495–498 (1998).
   PubMed Web of Science ®Google Scholar
• Autret E, Berjot M, Jonville-Bera AP, Aubry MC, Moraine C. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet350, 339 (1997).
   PubMed Web of Science ®Google Scholar
• Ciprandi G , Liccardi G, D’Amato G et al. Treatment of allergic diseases during pregnancy. J. Investig. Allergol. Clin. Immunol.7, 557–565 (1997).
   PubMed Web of Science ®Google Scholar
• Einarson A, Bailey B, Jung G, Spizzirri D, Baillie M, Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann. Allergy Asthma Immunol.78, 183–186 (1997).
   PubMed Web of Science ®Google Scholar
• Loebstein R, Lalkin A, Addis A et al. Pregnancy outcome after gestational exposure to terfenadine: a multicenter, prospective controlled study. J. Allergy Clin. Immunol.104, 953–956 (1999).
   PubMed Web of Science ®Google Scholar
• CDC. Evaluation of an association between loratadine and hypospadias – United States, 1997–2001. Morb. Mortal. Wkly Rep.53, 219–221 (2004).
   PubMedGoogle Scholar
• Gilbert C, Mazzotta P, Loebstein R, Koren G. Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. Drug Saf.28, 707–719 (2005).
   PubMed Web of Science ®Google Scholar
• Prenner BM. Neonatal withdrawal syndrome associated with hydroxyzine hydrochloride. Am. J. Dis. Child131, 529–30 (1977).
   PubMedGoogle Scholar
• Wendel GD Jr, Sheffield JS, Hollier LM, Hill JB, Ramsey PS, Sanchez PJ. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin. Infect. Dis.35(Suppl. 2), S200–S209 (2002).
   PubMed Web of Science ®Google Scholar
• Korzeniowski OM. Antibacterial agents in pregnancy. Infect. Dis. Clin. North Am.9, 639–651 (1995).
   PubMed Web of Science ®Google Scholar
• Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case-control study. Am. J. Obstet. Gynecol.184, 1289–1296 (2001).
   PubMed Web of Science ®Google Scholar
• Czeizel C, Rockenbauer M. A population based case–control teratologic study of oral metronidazole treatment during pregnancy. Br. J. Obstet. Gynaecol.105, 322–327 (1998).
   PubMedGoogle Scholar
• Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand. J. Infect. Dis.32, 309–313 (2000).
   PubMed Web of Science ®Google Scholar
• Czeizel AE, Puho E, Sorensen HT, Olsen J. Possible association between different congenital abnormalities and use of different sulfonamides during pregnancy. Congenit. Anom. (Kyoto)44, 79–86 (2004).
   PubMedGoogle Scholar
• Czeizel AE, Kazy Z, Vargha P. Vaginal treatment with povidone–iodine suppositories during pregnancy. Int. J. Gynec. Obstet.84, 83–85 (2004).
   PubMed Web of Science ®Google Scholar
• Moudgal VV, Sobel JD. Antifungal drugs in pregnancy: a review. Expert Opin. Drug Saf.2, 475–483 (2003).
   PubMedGoogle Scholar
• Money DM. Antiviral and antiretroviral use in pregnancy. Obstet. Gynecol. Clin. North Am.30, 731–749 (2003).
   PubMed Web of Science ®Google Scholar
• Einarson A, Costei A, Kalra S, Rouleau M, Koren G. The use of topical 5% imiquimod during pregnancy: a case series. Reprod. Toxicol.21, 1–2 (2006).
   PubMed Web of Science ®Google Scholar
• Czeizel AE. Population-based case–control study of teratogenic potential of corticosteroids. Teratology56, 335–340 (1997).
   PubMedGoogle Scholar
• Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst. Rev.2, CD002859 (2005).
   Google Scholar
• Norgard B, Puho E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case–control study. Am. J. Obstet. Gynecol.192, 922–923 (2005).
   PubMed Web of Science ®Google Scholar
• Gutierrez MJ, Acebedo-Ribo M, Garcia-Donaire JA et al. Pregnancy in renal transplant recipients. Transplant Proc.37, 3721–3722 (2005).
   PubMed Web of Science ®Google Scholar
• Janssen NM, Genta MS. The effect of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation. Arch. Intern. Med.160, 610–619 (2000).
   PubMed Web of Science ®Google Scholar
• Papo T, Wechsler B, Bletry O, Piette A, Godeau P, Piette JC. Pregnancy in relapsing polychondritis. 25 pregnancies in 11 patients. Arthritis Rheum.40, 1245–1249 (1997).
   PubMed Web of Science ®Google Scholar
• Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin. Arthritis Rheum.35, 112–121 (2005).
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ172, 1179–1180 (2005).
   PubMed Web of Science ®Google Scholar